We are delighted to announce that the Parkwalk Opportunities Fund and the Parkwalk Technology Fund VII have invested in Congenica Limited, which spun out of the Wellcome Trust Sanger Institute and Department of Health. Congenica has developed software that enables the accurate, rapid and scalable clinical interpretation of genetic and clinical data.
Congenica’s technology is based on ground breaking research from the Deciphering Developmental Disorders (DDD) Study. This study collected genetic data from over 13,600 children (plus another 19,400 mothers and fathers) at 24 UK NHS labs and has so far been able to identify 30 genes that were not previously known to be associated with developmental disorders. Results were published in Lancet and Nature in 2015, but the data will continue to be analysed for additional novel discoveries until 2021.